Name
RF6-01: (T-DXd) vs (T-DM1) in patients with (HER2+) primary breast cancer (BC) with residual invasive disease after neoadjuvant therapy: Interim analysis of DESTINY-Breast05 - Commentary By: Giuseppe Curigliano, MD, PhD
Date & Time
Tuesday, December 2, 2025
Speakers
Virtual Session Link
Total Minutes
04:59
OnDemand Video URL